Which has better earnings and valuation, NTRA or ASND?

Natera has higher revenue and earnings than Ascendis Pharma A/S. Natera is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Natera $2.31B 20.03 -$208.16M -$1.14 N/A Ascendis Pharma A/S $814.57M 19.90 -$258M $12.89 20.16

Does the media refer more to NTRA or ASND?

In the previous week, Natera had 42 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 47 mentions for Natera and 5 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.54 beat Natera's score of 0.27 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 15 Very Positive mention(s) 7 Positive mention(s) 10 Neutral mention(s) 5 Negative mention(s) 2 Very Negative mention(s) Neutral Ascendis Pharma A/S 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, ARGX or ASND?

argenex has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 14.25 $1.29B $28.66 33.58 Ascendis Pharma A/S $814.57M 19.90 -$258M $12.89 20.16

Does the media refer more to ARGX or ASND?

In the previous week, argenex had 11 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 16 mentions for argenex and 5 mentions for Ascendis Pharma A/S. argenex's average media sentiment score of 0.61 beat Ascendis Pharma A/S's score of 0.54 indicating that argenex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 6 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ASND or RVMD?

In the previous week, Revolution Medicines had 37 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 42 mentions for Revolution Medicines and 5 mentions for Ascendis Pharma A/S. Revolution Medicines' average media sentiment score of 0.62 beat Ascendis Pharma A/S's score of 0.54 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 14 Very Positive mention(s) 6 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, BIIB or ASND?

Biogen has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $9.89B 3.81 $1.29B $2.34 108.92 Ascendis Pharma A/S $814.57M 19.90 -$258M $12.89 20.16

Does the media favor BIIB or ASND?

In the previous week, Biogen had 19 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 24 mentions for Biogen and 5 mentions for Ascendis Pharma A/S. Biogen's average media sentiment score of 1.18 beat Ascendis Pharma A/S's score of 0.54 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 18 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Ascendis Pharma A/S 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, GMAB or ASND?

Genmab A/S has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genmab A/S $3.72B 9.36 $963M $1.17 47.69 Ascendis Pharma A/S $814.57M 19.90 -$258M $12.89 20.16

Does the media refer more to GMAB or ASND?

In the previous week, Genmab A/S had 11 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 16 mentions for Genmab A/S and 5 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.54 beat Genmab A/S's score of 0.52 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Ascendis Pharma A/S 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ascendis Pharma A/S (ASND) Competitors

$259.85 +3.03 (+1.18%)

Closing price 11/9/2026 04:00 PM Eastern

Extended Trading

$259.86 +0.01 (+0.00%)

As of 07:28 AM Eastern

Compare

ASND vs. NTRA, ARGX, RVMD, BIIB, and GMAB

Should you buy Ascendis Pharma A/S stock or one of its competitors? Ascendis Pharma A/S's main competitors and comparable companies include Natera (NTRA), argenex (ARGX), Revolution Medicines (RVMD), Biogen (BIIB), and Genmab A/S (GMAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ascendis Pharma A/S compare to Natera?

Natera (NASDAQ:NTRA) and Ascendis Pharma A/S (NASDAQ:ASND) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

99.9% of Natera shares are owned by institutional investors. 5.1% of Natera shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Ascendis Pharma A/S has a net margin of 70.99% compared to Natera's net margin of -7.11%. Ascendis Pharma A/S's return on equity of 32.54% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.38%	-7.87%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

Natera has higher revenue and earnings than Ascendis Pharma A/S. Natera is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	20.03	-$208.16M	-$1.14	N/A
Ascendis Pharma A/S	$814.57M	19.90	-$258M	$12.89	20.16

Natera has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

In the previous week, Natera had 42 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 47 mentions for Natera and 5 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.54 beat Natera's score of 0.27 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	15 Very Positive mention(s)	7 Positive mention(s)	10 Neutral mention(s)	5 Negative mention(s)	2 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Natera presently has a consensus price target of $394.31, suggesting a potential upside of 23.07%. Ascendis Pharma A/S has a consensus price target of $305.95, suggesting a potential upside of 17.74%. Given Natera's higher possible upside, equities analysts plainly believe Natera is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	2 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.83
Ascendis Pharma A/S	0 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.90

Summary

Natera and Ascendis Pharma A/S tied by winning 8 of the 16 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to argenex?

argenex (NASDAQ:ARGX) and Ascendis Pharma A/S (NASDAQ:ASND) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

In the previous week, argenex had 11 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 16 mentions for argenex and 5 mentions for Ascendis Pharma A/S. argenex's average media sentiment score of 0.61 beat Ascendis Pharma A/S's score of 0.54 indicating that argenex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	6 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

argenex has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	14.25	$1.29B	$28.66	33.58
Ascendis Pharma A/S	$814.57M	19.90	-$258M	$12.89	20.16

60.3% of argenex shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Ascendis Pharma A/S has a net margin of 70.99% compared to argenex's net margin of 31.66%. argenex's return on equity of 47.70% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.66%	47.70%	40.12%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

argenex presently has a consensus target price of $1,158.76, suggesting a potential upside of 20.42%. Ascendis Pharma A/S has a consensus target price of $305.95, suggesting a potential upside of 17.74%. Given argenex's higher probable upside, analysts plainly believe argenex is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	6 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.82
Ascendis Pharma A/S	0 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.90

Summary

argenex beats Ascendis Pharma A/S on 13 of the 17 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to Revolution Medicines?

Ascendis Pharma A/S (NASDAQ:ASND) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

Ascendis Pharma A/S has a net margin of 70.99% compared to Revolution Medicines' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Revolution Medicines	N/A	-89.91%	-57.76%

In the previous week, Revolution Medicines had 37 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 42 mentions for Revolution Medicines and 5 mentions for Ascendis Pharma A/S. Revolution Medicines' average media sentiment score of 0.62 beat Ascendis Pharma A/S's score of 0.54 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	14 Very Positive mention(s)	6 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

94.3% of Revolution Medicines shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 7.6% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Ascendis Pharma A/S presently has a consensus price target of $305.95, suggesting a potential upside of 17.74%. Revolution Medicines has a consensus price target of $263.15, suggesting a potential upside of 31.48%. Given Revolution Medicines' stronger consensus rating and higher possible upside, analysts plainly believe Revolution Medicines is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.90
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.92

Ascendis Pharma A/S has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.44, indicating that its stock price is 44% more volatile than the broader market.

Ascendis Pharma A/S has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	19.90	-$258M	$12.89	20.16
Revolution Medicines	$11.58M	3,704.68	-$1.13B	-$9.11	N/A

Summary

Revolution Medicines beats Ascendis Pharma A/S on 9 of the 16 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to Biogen?

Biogen (NASDAQ:BIIB) and Ascendis Pharma A/S (NASDAQ:ASND) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Biogen has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.81	$1.29B	$2.34	108.92
Ascendis Pharma A/S	$814.57M	19.90	-$258M	$12.89	20.16

Ascendis Pharma A/S has a net margin of 70.99% compared to Biogen's net margin of 3.37%. Ascendis Pharma A/S's return on equity of 32.54% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	3.37%	9.38%	5.69%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

Biogen presently has a consensus target price of $254.41, indicating a potential downside of 0.18%. Ascendis Pharma A/S has a consensus target price of $305.95, indicating a potential upside of 17.74%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	10 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.67
Ascendis Pharma A/S	0 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.90

87.9% of Biogen shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Biogen had 19 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 24 mentions for Biogen and 5 mentions for Ascendis Pharma A/S. Biogen's average media sentiment score of 1.18 beat Ascendis Pharma A/S's score of 0.54 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	18 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Ascendis Pharma A/S	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market.

Summary

Ascendis Pharma A/S beats Biogen on 9 of the 17 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Ascendis Pharma A/S (NASDAQ:ASND) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

7.1% of Genmab A/S shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Genmab A/S had 11 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 16 mentions for Genmab A/S and 5 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.54 beat Genmab A/S's score of 0.52 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Ascendis Pharma A/S	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	9.36	$963M	$1.17	47.69
Ascendis Pharma A/S	$814.57M	19.90	-$258M	$12.89	20.16

Genmab A/S currently has a consensus price target of $53.61, indicating a potential downside of 3.92%. Ascendis Pharma A/S has a consensus price target of $305.95, indicating a potential upside of 17.74%. Given Ascendis Pharma A/S's higher probable upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.92
Ascendis Pharma A/S	0 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.90

Genmab A/S has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

Ascendis Pharma A/S has a net margin of 70.99% compared to Genmab A/S's net margin of 19.08%. Ascendis Pharma A/S's return on equity of 32.54% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

Summary

Genmab A/S beats Ascendis Pharma A/S on 9 of the 17 factors compared between the two stocks.

Get Ascendis Pharma A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASND vs. The Competition

Export

Metric	Ascendis Pharma A/S	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.09B	$4.21B	$7.92B	$12.28B
Dividend Yield	N/A	3.62%	2.47%	4.41%
P/E Ratio	20.16	32.73	36.04	30.48
Price / Sales	19.90	17.28	9.03	5.96
Price / Cash	N/A	23.45	21.38	22.89
Price / Book	-87.49	4.54	4.78	4.02
Net Income	-$258M	-$22.13M	$3.50B	$381.74M
7 Day Performance	3.87%	0.95%	1.24%	0.06%
1 Month Performance	13.36%	-6.52%	-3.59%	-5.69%
1 Year Performance	32.57%	4.22%	3.88%	-5.49%

Ascendis Pharma A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASND Ascendis Pharma A/S	4.564 of 5 stars	$259.85 +1.2%	$305.95 +17.7%	+31.4%	$16.09B	$814.57M	20.16	1,189	Upcoming Earnings Analyst Upgrade
NTRA Natera	4.1064 of 5 stars	$378.92 -8.5%	$394.31 +4.1%	+60.5%	$61.18B	$2.31B	N/A	6,140	Earnings Report Analyst Forecast
ARGX argenex	4.7081 of 5 stars	$874.97 -2.0%	$1,158.76 +32.4%	+12.6%	$56.08B	$4.25B	30.53	1,863	News Coverage
RVMD Revolution Medicines	3.4887 of 5 stars	$188.17 -1.6%	$242.90 +29.1%	+228.1%	$40.45B	$11.58M	N/A	883	Earnings Report Analyst Upgrade Analyst Revision
BIIB Biogen	3.0576 of 5 stars	$249.01 -1.8%	$252.34 +1.3%	+63.9%	$36.06B	$9.89B	20.72	7,500	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASND) was last updated on 11/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ascendis Pharma A/S (ASND) Competitors

ASND vs. NTRA, ARGX, RVMD, BIIB, and GMAB

How does Ascendis Pharma A/S compare to Natera?

Summary

How does Ascendis Pharma A/S compare to argenex?

Summary

How does Ascendis Pharma A/S compare to Revolution Medicines?

Summary

How does Ascendis Pharma A/S compare to Biogen?

Summary

How does Ascendis Pharma A/S compare to Genmab A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASND vs. The Competition

Ascendis Pharma A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ascendis Pharma A/S (ASND) Competitors

ASND vs. NTRA, ARGX, RVMD, BIIB, and GMAB

How does Ascendis Pharma A/S compare to Natera?

Do insiders & institutionals hold more shares of NTRA or ASND?

Is NTRA or ASND more profitable?

Which has better earnings and valuation, NTRA or ASND?

Which has more risk & volatility, NTRA or ASND?

Does the media refer more to NTRA or ASND?

Do analysts prefer NTRA or ASND?

Summary

How does Ascendis Pharma A/S compare to argenex?

Does the media refer more to ARGX or ASND?

Which has more risk & volatility, ARGX or ASND?

Which has better earnings & valuation, ARGX or ASND?

Do insiders and institutionals hold more shares of ARGX or ASND?

Is ARGX or ASND more profitable?

Do analysts recommend ARGX or ASND?

Summary

How does Ascendis Pharma A/S compare to Revolution Medicines?

Is ASND or RVMD more profitable?

Does the media prefer ASND or RVMD?

Do insiders & institutionals believe in ASND or RVMD?

Do analysts prefer ASND or RVMD?

Which has more volatility and risk, ASND or RVMD?

Which has preferable earnings & valuation, ASND or RVMD?

Summary

How does Ascendis Pharma A/S compare to Biogen?

Which has better valuation and earnings, BIIB or ASND?

Is BIIB or ASND more profitable?

Do analysts recommend BIIB or ASND?

Do institutionals and insiders believe in BIIB or ASND?

Does the media favor BIIB or ASND?

Which has more risk and volatility, BIIB or ASND?

Summary

How does Ascendis Pharma A/S compare to Genmab A/S?

Do insiders and institutionals believe in GMAB or ASND?

Does the media refer more to GMAB or ASND?

Which has preferable valuation and earnings, GMAB or ASND?

Do analysts rate GMAB or ASND?

Which has more volatility & risk, GMAB or ASND?

Is GMAB or ASND more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASND vs. The Competition

Ascendis Pharma A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools